Literature DB >> 24615189

Influence of experience and qualification on PET-based target volume delineation. When there is no expert--ask your colleague.

C Doll1, V Duncker-Rohr, G Rücker, M Mix, M MacManus, D De Ruysscher, W Vogel, J G Eriksen, W Oyen, A-L Grosu, W Weber, U Nestle.   

Abstract

BACKGROUND AND
PURPOSE: The integration of positron emission tomography (PET) information for target volume delineation in radiation treatment planning is routine in many centers. In contrast to automatic contouring, research on visual-manual delineation is scarce. The present study investigates the dependency of manual delineation on experience and qualification. PATIENTS AND METHODS: A total of 44 international interdisciplinary observers each defined a [(18)F]fluorodeoxyglucose (FDG)-PET based gross tumor volume (GTV) using the same PET/CT scan from a patient with lung cancer. The observers were "experts" (E; n = 3), "experienced interdisciplinary pairs" (EP; 9 teams of radiation oncologist (RO) + nuclear medicine physician (NP)), "single field specialists" (SFS; n = 13), and "students" (S; n = 10). Five automatic delineation methods (AM) were also included. Volume sizes and concordance indices within the groups (pCI) and relative to the experts (eCI) were calculated.
RESULTS: E (pCI = 0.67) and EP (pCI = 0.53) showed a significantly higher agreement within the groups as compared to SFS (pCI = 0.43, p = 0.03, and p = 0.006). In relation to the experts, EP (eCI = 0.55) showed better concordance compared to SFS (eCI = 0.49) or S (eCI = 0.47). The intermethod variability of the AM (pCI = 0.44) was similar to that of SFS and S, showing poorer agreement with the experts (eCI = 0.35).
CONCLUSION: The results suggest that interdisciplinary cooperation could be beneficial for consistent contouring. Joint delineation by a radiation oncologist and a nuclear medicine physician showed remarkable agreement and better concordance with the experts compared to other specialists. The relevant intermethod variability of the automatic algorithms underlines the need for further standardization and optimization in this field.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24615189     DOI: 10.1007/s00066-014-0644-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  23 in total

1.  18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis.

Authors:  U Nestle; K Walter; S Schmidt; N Licht; C Nieder; B Motaref; D Hellwig; M Niewald; D Ukena; C M Kirsch; G W Sybrecht; K Schnabel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-06-01       Impact factor: 7.038

2.  Comparative study with new accuracy metrics for target volume contouring in PET image guided radiation therapy.

Authors:  Tony Shepherd; Mika Teras; Reinhard R Beichel; Ronald Boellaard; Michel Bruynooghe; Volker Dicken; Mark J Gooding; Peter J Julyan; John A Lee; Sébastien Lefèvre; Michael Mix; Valery Naranjo; Xiaodong Wu; Habib Zaidi; Ziming Zeng; Heikki Minn
Journal:  IEEE Trans Med Imaging       Date:  2012-06-04       Impact factor: 10.048

Review 3.  PET/CT and radiotherapy.

Authors:  C Messa; N Di Muzio; M Picchio; M C Gilardi; V Bettinardi; F Fazio
Journal:  Q J Nucl Med Mol Imaging       Date:  2006-03       Impact factor: 2.346

4.  Where do we draw the line? Contouring tumors on positron emission tomography/computed tomography.

Authors:  Michael P Macmanus; Rodney J Hicks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-01       Impact factor: 7.038

5.  Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.

Authors:  Ursula Nestle; Stephanie Kremp; Andrea Schaefer-Schuler; Christiane Sebastian-Welsch; Dirk Hellwig; Christian Rübe; Carl-Martin Kirsch
Journal:  J Nucl Med       Date:  2005-08       Impact factor: 10.057

6.  Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis.

Authors:  Roel J H M Steenbakkers; Joop C Duppen; Isabelle Fitton; Kirsten E I Deurloo; Lambert J Zijp; Emile F I Comans; Apollonia L J Uitterhoeve; Patrick T R Rodrigus; Gijsbert W P Kramer; Johan Bussink; Katrien De Jaeger; José S A Belderbos; Peter J C M Nowak; Marcel van Herk; Coen R N Rasch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-28       Impact factor: 7.038

7.  The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.

Authors:  Hani Ashamalla; Sameer Rafla; Kapila Parikh; Bahaa Mokhtar; Ganesh Goswami; Shravan Kambam; Hussain Abdel-Dayem; Adel Guirguis; Pamela Ross; Alex Evola
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-24       Impact factor: 7.038

8.  The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.

Authors:  Wouter van Elmpt; Dirk De Ruysscher; Anke van der Salm; Annemarie Lakeman; Judith van der Stoep; Daisy Emans; Eugène Damen; Michel Öllers; Jan-Jakob Sonke; José Belderbos
Journal:  Radiother Oncol       Date:  2012-04-06       Impact factor: 6.280

9.  (18)F-fluorodeoxyglucose positron emission tomography-based assessment of local failure patterns in non-small-cell lung cancer treated with definitive radiotherapy.

Authors:  Sonal Sura; Carlo Greco; Daphna Gelblum; Ellen D Yorke; Andrew Jackson; Kenneth E Rosenzweig
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-01       Impact factor: 7.038

Review 10.  Biological imaging in radiation therapy: role of positron emission tomography.

Authors:  Ursula Nestle; Wolfgang Weber; Michael Hentschel; Anca-Ligia Grosu
Journal:  Phys Med Biol       Date:  2008-12-05       Impact factor: 3.609

View more
  7 in total

1.  4D-Listmode-PET-CT and 4D-CT for optimizing PTV margins in gastric lymphoma : Determination of intra- and interfractional gastric motion.

Authors:  Gabriele Reinartz; Uwe Haverkamp; Ramona Wullenkord; Philipp Lehrich; Jan Kriz; Florian Büther; Klaus Schäfers; Michael Schäfers; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2016-02-22       Impact factor: 3.621

Review 2.  Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization.

Authors:  Michael MacManus; Sarah Everitt; Tanja Schimek-Jasch; X Allen Li; Ursula Nestle; Feng-Ming Spring Kong
Journal:  Transl Lung Cancer Res       Date:  2017-12

Review 3.  The developing role of FDG PET imaging for prognostication and radiotherapy target volume delineation in non-small cell lung cancer.

Authors:  Tom Konert; Jeroen B van de Kamer; Jan-Jakob Sonke; Wouter V Vogel
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 4.  Functional imaging for radiotherapy treatment planning: current status and future directions-a review.

Authors:  D Thorwarth
Journal:  Br J Radiol       Date:  2015-04-01       Impact factor: 3.039

5.  Use of Positron Emission Tomography/Computed Tomography in Radiation Treatment Planning for Lung Cancer.

Authors:  Kezban Berberoğlu
Journal:  Mol Imaging Radionucl Ther       Date:  2016-06-05

6.  EANM/SNMMI practice guideline for [18F]FDG PET/CT external beam radiotherapy treatment planning in uterine cervical cancer v1.0.

Authors:  Judit A Adam; Annika Loft; Cyrus Chargari; Roberto C Delgado Bolton; Elisabeth Kidd; Heiko Schöder; Patrick Veit-Haibach; Wouter V Vogel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-12-04       Impact factor: 9.236

Review 7.  Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.

Authors:  Sofia C Vaz; Judit A Adam; Roberto C Delgado Bolton; Pierre Vera; Wouter van Elmpt; Ken Herrmann; Rodney J Hicks; Yolande Lievens; Andrea Santos; Heiko Schöder; Bernard Dubray; Dimitris Visvikis; Esther G C Troost; Lioe-Fee de Geus-Oei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-13       Impact factor: 10.057

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.